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ABSTRACT Monoclonal antibody NC6.8 binds the superpotent sweetener ligand N-(p-cyanophenyl)-N'-(diphenylmethyl)
guanidineacetic acid with high affinity (Kd = 53 nM). Using computer-aided molecular modeling and several experimental
techniques, such as competitive ligand binding, absorbance spectroscopy, and fluorescence spectroscopy, we have
predicted the structure of the variable domain fragment (Fv) and identified the key residues in the combining site of the
antibody. We have identified nine specific amino acids as being involved in ligand recognition and complexation. Most notable
are H:33W, which is responsible for ligand-induced tryptophan fluorescence quenching, H:56R, which forms a salt bridge with
the carboxylate moiety of the ligand, and L:34H, which, deep in the binding site, interacts with the cyanophenyl portion of the
ligand. Two residues located deep in the putative binding pocket, H:35E and H:50E, provide the negatively charged potential
for interaction with the protonated aryl nitrogen and the positive guanidinium group. These modeling predictions were made
before the solution of high-resolution structures of the native Fab (2.6 A) and the Fab-ligand complex (2.2 A). Comparisons
between the theoretical model and experimental native and liganded Fab structures are made.
INTRODUCTION
Structural studies of antibody fragments have provided a
basis for establishing the uniqueness of the (Ig) fold and the
specificity of antigen recognition (Davies and Metzger,
1983; Davies et al., 1990; Poljak et al., 1976). The Ig fold
is characterized by the (3-barrel topology of each of the
domains, combined with a high degree of conservation in
specific packing residues, 3-strand turns, and overall inter-
domain packing geometry (Chothia et al., 1985; Padlan,
1990; Tramontano and Lesk, 1992). The two polypeptide
chains, heavy (H) and light (L), contain four and two
domains, respectively, and associate through a disulfide link
and numerous nonbonded hydrophobic contacts. In addition
to a common fold topology, all Ig have the antigen-com-
bining site located at the en face, or N-terminal, portion of
the molecule, where the 13 strands form turns. The frequen-
cies of specific residues in these loops or turns are more
variable between antibodies than those for the remainder of
the molecules. Such "hypervariable residues" appear to
determine much of the antigen specificity of a given anti-
body and are termed the complementarity-determining re-
gions (CDR).
Given these highly conserved structural and functional
motifs, computer-aided molecular modeling (CAMM) anti-
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body fragment structures from the amino acid sequence has
become possible. There have been numerous efforts in the
past decade that reflect this approach (Bruccoleri et al.,
1988; Chothia & Lesk, 1987; Chothia et al., 1989; Chothia
et al., 1986; de la Paz et al., 1986). All the methods em-
ployed for modeling antibody structures have been knowl-
edge based. The basic theme in these methods has been to
compare the antibody sequence to be modeled with those
antibody sequences whose three-dimensional structures are
available. The antibody with the highest sequence homol-
ogy is then chosen as the scaffold for homology modeling
the antibody whose structure is desired. Various refinement
schemes are then used on the initial model that is formed by
combination of replacement, addition, and deletion on the
scaffold structure.
The primary difficulty in CAMM lies in the CDR loops
themselves, because they exhibit great variation in size and
composition between different antibodies. A powerful ap-
proach for modeling the loops has been developed by Bruc-
coleri and co-workers (Bruccoleri and Karplus, 1987; Bruc-
coleri et al., 1988). CONGEN, a conformational search
algorithm developed by Bruccoleri et al., has been able to
calculate low-energy loop configurations of Fv fragments of
McPC603 and HyHEL-5 (Bruccoleri et al., 1988) and
AN02 (Bassolino-Klimas et al., 1993); these models agree
well with known crystal structures. In this approach, first
the loops are constructed on a framework using the chain
closing algorithm of Go and Scheraga and then a systematic
conformational search of the backbone torsions on a grid is
carried out. For loop reconstruction, the order L2, Hi, L3,
H2, H3, Li has been used consistent with the rationale that
loops that span the region closest to the beta barrel in the
known structures shape the topology better. In the above
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studies the molecular mechanics calculations were carried
out in vacuo, whereas Martin et al. (1989) used a modified
version of CONGEN in which solvent-modified potentials
are used for molecular mechanics.
An important observation concerning the antibody hyper-
variable regions was made by Chothia and co-workers
(Chothia and Lesk, 1987; Chothia et al., 1989). Although
the loop region residues are hypervariable, it was found that
a few key positions in these loops have unique configura-
tions and that these canonical residue configurations are
conserved across antibodies. The canonical region con-
straints have been used in modeling D1.3, and this results in
very good agreement with the crystal structure. Canonical
region constraints have also been used in modeling antimor-
phine and antihaloperidol antibody loops (Kussie et al.,
1991; Anchin et al., 1991). For small antigen or hapten
binding the large body of knowledge that can be gleaned
from experimental competitive antigen binding data has
been used for effective modeling of the antigen-combining
sites (Jackson et al., 1992; Kussie et al., 1991; Sherman &
Bolger, 1988).
We report the CAMM and prediction of the ligand bind-
ing site for monoclonal antibody NC6.8, which is specific
for the superpotent sweetener N-(p-cyanophenyl)-N'(diphe-
nylmethyl)guanidineacetic acid (Anchin and Linthicum,
1993). Our CAMM studies were aided by a variety of
different experimental results that examined the binding of
the sweetener ligand to the antibody. Results from compet-
itive analog radioimmunoassays, pH titrations of radio-
ligand binding, and fluorescence and absorption spectros-
copy were all used to assist the CAMM studies and to
identify the key residues in the combining site of the anti-
body. These results were directly compared with the high-
resolution 2.6- and 2.2-A Fab crystal structures of the native
and complexed forms, respectively, of mAb NC6.8 recently
obtained by Guddat and co-workers (Guddat et al., 1994).
These studies are important to the understanding of the
specificity of antibody-antigen complexes and may also
shed light on the putative receptor recognition motifs for
superpotent sweeteners.
MATERIALS AND METHODS
Computer-aided modeling and refinement
A number of different computer algorithms were used in this investigation
to model and display graphically the Fv region of NC6.8. Programs
ABalign and ABbuild of the ABGEN algorithm, written by us, were used
to select "parent structures" and generate a first-order Fv model (C.
Mandal, D. S. Linthicum, and S. Subramaniam, unpublished programs).
Each of the H- and L-chain sequences of the Fv fragment of NC6.8 is
divided into seven segments, four framework (FR) regions and three
CDRs. The FR segments constitute the more conserved part and have
several residues that are strictly conserved or conservatively replaced.
These segments form the core of the (3-barrel structure. Table 1 lists the
residues that are conserved in more than 95% of the Ig sequences reported
in the Kabat database of Ig sequences (Kabat et al., 1991) and are also
conserved in NC6.8. In as much as these residues occur at exactly the same
relative position in all the immunoglobin sequences they serve as finger-
print residues to enforce alignment.
TABLE I Conserved residues in immunoglobulin sequences
L Chain H Chain
5:T 61:R 82:D 4:L 86:D 106:G
6:Q 62:F 86:Y 8:G 88:A 107:T
16:G 64:G 88:C 22:C 90:Y 110:T
23:C 65:S 98:F 26:G 92:C 111:V
35:W 73:L 99:G 36:W 103:W 112:S
59:P 75:1 101:G 45:L 104:G 102:T
Conserved in 95-99% in known sequences (Kabat et al., 1991).
The H- (L-) chain framework scaffolds are chosen based on the highest
sequence homology. Because H and L chains are aligned separately, two
different parent proteins contribute chains to the scaffold. The sizes of the
CDRs for the parent antibody fragments match that of NC6.8, and hence no
effort was made to graft CDR fragments from other antibody structures.
The first stage in the structural modeling entails building the H-L joint
chain framework scaffold from the best model chains. As the H and L
chains of the test model are contributed by different parent antibody
structures, the best H-L framework structural alignment was accomplished
by a least-squares refinement with reference to the two parent structures.
All atoms in the chains were used in the least-squares refinement.
Once the entire framework scaffold model, including H and L chain,
was obtained, the residue replacements that were required was carried out.
Because all these mutations in the FR region were highly conservative
substitutions, no backbone refinement was carried out. The side-chain
torsions of the residues replaced in the FR region were explored for the best
contact and packing, defined by a strict van der Waals criterion, and the
resulting model was used as the model for the framework region. More
substitutions were required in the CDRs, and the resulting CDR configu-
rations required further refinement.
Molecular dynamics refinement
The refinement of the initial model was carried out by the use of molecular
mechanics and molecular dynamics techniques. The XPLOR (Brunger et
al., 1987) program was used to generate the low-energy conformations of
the CDR loops. An approximate solvent screening effect was introduced by
use of the distance-dependent dielectric term in the electrostatic potential
term. Harmonic constraints of 50 kcal/mol A2 were applied to fix the entire
framework region of the model. Chothia and Lesk (1987) observed certain
canonical configurations in the CDRs among different antibodies. The
CDRs of our model were examined for any of these canonical loop
conformations. Distance restraints were then applied to the atoms involved
in the canonical conformations for effective modeling of the loop regions.
The system was subjected to 20 ps of molecular dynamics at 300 K, and
configurations were obtained through quenching of trajectories at 2-ps
intervals. The L- and H-chain CDRs were modeled in the order L2, Hi, L3,
H2, H3, and Li as proposed by Bruccoleri and co-workers (Bruccoleri et
al., 1988). Electrostatic surface renderings of the models were generated by
the NCVIEW algorithm, which uses the van der Waals surface derived
from the radii values compiled by Bondi (1964).
Experimental methods used for modeling
Monoclonal antibodies
We have produced a library of monoclonal antibodies against the guanidine
sweetener N-(p-cyanophenyl)-N'-(diphenylmethyl) guanidineacetic acid
(Anchin and Linthicum, 1993). This ligand is 200,000 times more potent
than sucrose as measured in a threshold taste test for sucrose (Muller et al.,
1992). The structure of the ligand is depicted in Fig. 1. The immunogen
was prepared by conjugation of the ligand to bovine serum albumin
through the paraposition of one of the phenyl rings; this material was
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FIGURE 1 Ligand N-(p-cyanophenyl)-N'-(diphenylmethyl)guanidine-
acetic acid has a potency more than 200,000 times that of sucrose as
assessed by a threshold taste test for sweetness.
kindly provided by Dr. Srinivasan Nagarajan and Dr. Jeff Carter of the
NutraSweet Company (Mt. Prospect, IL).
Radioligand experiments
A liquid phase radioimmunoassay for the separation of bound and unbound
tritiated ligand was used for detailed ligand binding analysis of the anti-
body (Kussie et al., 1989). This assay employs 1-ml syringe barrel mini-
columns of Sephadex G-25 that separate the mAb-bound ligand from the
free ligand containing supematant. The mAb samples used in these assays
were from either hybridoma tissue culture supernatant or hybridoma ascites
from which Ig was purified by G-protein affinity chromatography. Titra-
tion assays were performed by incubating a single concentration of radio-
labeled ligand ([3H]-ligand; 48 Ci/mmol) with serial dilutions of mAb to
determine a proper dilution for subsequent saturation assays. Competitive
ligand binding experiments with different ligand analogs and IC50 deter-
minations were carried out by standard procedures (Kussie et al., 1989).
Statistical analyses and plotting of data were accomplished with the pro-
grams EBDA and LIGAND (McPherson, 1985).
The radioimmunoassay was used to determine the pH sensitivity of
ligand binding to NC6.8. The assay was performed in 0.16-M NaCl
containing the following buffers: glycine-HCl buffer (pH 3.3), acetate
buffer (pH 4.1 to 5.5), phosphate buffer (pH 6.1 to 7.5), tris-HCl buffer (pH
7.8 to 9.1), carbonate buffer (pH 9.5 to 11.2), and phosphate-NaOH buffer
(pH 12.0). All assay components ([3H]-ligand and mAb) were diluted in
the different buffers and incubated for 2 h at room temperature. The
concentration of antibody was sufficient to bind approximately 50% of the
[3H]-ligand radioligand. For each buffer, the amount of nonspecific [3H]-
ligand binding was obtained in control tubes without mAb.
Spectroscopic methods
Absorption spectral measurements were carried out with a Shimadzu
PC2101 UV-Visible double-beam spectrophotometer (Shimadzu Scientific
Instruments, Inc., Columbia, MD). The spectra were recorded in the
wavelength range of 230-800 nm. A slit width of 2.0 nm and a fast scan
were employed. Charge-transfer complex band formation was examined in
the absorbancy range of 0.3-0.5 (at 280 nm). Ligand solution was added
in microliter quantities to the solution containing mAb NC6.8, starting with
the lowest ligand concentration solution first. A spectral scan was carried
out after 2 min; the absorbance values did not change with longer reaction
time periods. An initial titration was performed to yield 30 data points for
a wide concentration range of the ligand before the data were analyzed.
Titrations were repeated for 20 data points in the narrow concentration
range of interest.
Fluorescence spectral measurements were made with a SLM 8000
spectrofluorimeter (SLM Instruments, Urbana, IL) equipped with a ther-
mostatic cell holder and magnetic stirrer. The excitation wavelength em-
ployed was 280 nm, and emission was monitored in the range of 310-370
nm; peak emission was usually near 335 nm. The excitation and emission
slit widths were maintained at 4 and 8 nm, respectively. The fluorescence
intensities were obtained as the ratio of a fluorescent beam to a straight-
through beam to compensate for fluctuations in lamp intensity. Emission
intensities at a single wavelength were also collected over a period of 10 s.
All spectral data were processed on a microcomputer dedicated to the SLM
8000. We previously described our procedures for corrections of emission
intensity to compensate for dilution and photobleaching effects (Droupadi
et al., 1993).
A double inverse plot of AF(FO - F.), where FO and Fi are the
fluorescence intensities in the absence and presence of ligand, respectively,
near the saturation point versus concentration of the ligand was constructed
to yield the maximum fluorescence quenching according to the method of
Lehrer (1971). Equilibrium association constants were evaluated according
to the method of Stinson and Holbrook (1973) using the equation
1/(1 - q)KA = [Li]/q - p[A;], where q, the fractional occupancy of binding
sites, is given by AF/AFa,, where AFmax is the maximum fluorescence
quenching obtained by the double inverse plot, KA is the intrinsic associ-
ation constant, p is the number of binding sites, and Li and Ai are the
concentrations of the ligand and the antibody, respectively. The natural
logarithm of KA calculated at different temperatures was plotted against the
inverse of absolute temperature (van't Hoff analysis) to evaluate the
enthalpic change (AH = -slope/R) involved in the binding process. The
change in the free energy (AG) of the system was obtained by the equation
AG = -RT In KA. The change in the entropy (AS) of the system was
calculated by the equation AG = AH - TAS.
RESULTS
The sequence of NC6.8 was compared against ten antibody
sequences with high-resolution structures as shown in Fig.
2 A and B (Suh et al., 1986; Fischmann et al., 1991; Herron
et al., 1989; Kratzin et al., 1989; Lascombe et al., 1992;
Padlan et al., 1989; Saul and Poljak, 1992; Sheriff et al.,
1987; Strong et al., 1991). For the L chain, the antifluores-
cein antibody (4FAB) had the highest score of 99, with no
deletions or additions required in the loop regions. The next
best match was with antibody McPC603 (2MCP) with a
score of 70 and a deletion in the CDRL1. There were eleven
replacements in the antifluorescein antibody, with four of
them in the FR1 and one each in CDR1, CDR2, and the
FR3, whereas the FR2 and CDR3 had two replacements
each. The statistics for the H chain showed that HyHel-5
antibody (2HFL) had the maximum score of 94, with no
deletions or additions required. The next best fit, the anti-
arsonate antibody R19.9 (2F19) had a score of 77 and had
eight deletions in the CDRH3 loop alone. There were twen-
ty-two replacements in the HyHel-5 antibody, six of which
were in the CDR3, five in the FR1, four in the FR3, three in
the CDR2, two in FR4, and one each in CDR1 and FR1.
Hence, an initial unrefined model was generated using the L
chain of 4FAB and the H-chain structure of 2HFL.
The starting model structure had a high-energy configu-
ration of 1.7 X 105 kcal/mol. The root-mean-square devia-
tion (rmsd) of the model structure against the x-ray native
structure showed a deviation of 2.3 A. This model was then
subjected to 200 steps of Powell's energy minimization,
resulting in a structure with an energy of -7.56 X 103
kcal/mol. The total energy of the structure varied from
Viswanathan et al. 743
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A
L-CHAIN
1 CDR1(26-32) CDR2(49-56) 70
NC6.8 ELvmtqSplslpvslgdqasiscrPsaslvhs*NantvlHwylqkpgqspkLlivvsnrf gvpdrfsgsgsgtA
1FDL diqmtqspaslsasvgetvtitcrasa******nihnvlawyqqkqgkspqllvyyttt1adgvpsrfsgsgsgtq
2F19 divltqspaslsaslgdrvtiscrasa******disnvlnwyqqkpdgtvklliyvtsrlhsgvpsrfsgsgsgtd
2FBJ eivltqspaitaas1gqkvtitcsass*******svsslhwyqqksgtspkpwiveisklasavparfsgsgsgts
2HFL divltqspaimsaspgekvtmtcsass*******svnvmywyqqksgtspkrwivdtsklasgvpvrfsgsgsgts
2IG2 qsvltqpps*asgtpgqrvtiscsgtssn****iasstvnwyqqlpgmapkllivrdamrysgvpdrfsgsksgas
2MCP divmtqspsslsvsagervtmsckssasllnsangknflawyqqkpgqppkllivaastresgvpdrftgsgsgtd
3HFM divltqspatlsvtpgnsvslscrasa******signnlhwyqqkshesprllikyasasi gipsrfsgsgsgtd
4FAB DVvmtqTplslpvslgdqasiscrSsaslvhs*OantvlRwylqkpgqspkVlivKvsnrfsgvpdrfsgsgsgtD
6FAB diqmtqipsslsaslgdrvsiscrasa******dinnflnwyqqkpdgtikllivftsrsasgvpsrfsgsgsgtd
7FAB asvltqpps*vsgapgqrvtisctgsss***niaaahnvkwyqqlpgtapkllifhnn*******arfsvsksgts
71 CDR3 (89-97) 106
NC6.8 ftlkisrveaedlgvyfcsaGthvr******Ytfgggtklei
1FDL yslkinslqpedfgsyyc hfwstO******rtfgggtk1ei
2F19 ysltisnlehediatyfcaaastlp******rtfgggtklei
2FBJ ysltintmeaedaaiyycaawtvnl******itfgagtklel
2HFL ysltissmetedaaeyycgawgrnp*******vtfgggtklei
2IG2 aslaigglqsedetdyycaawdvs1****nayfpgtgtkvtv
2MCP ftltissvqaedlavyycandhsvp******ltfgagtklei
3HFM ftlsinsvetedfgmyfcaasnswp******vtfgggtklei
4FAB ftlkisrveaedlgvyfcsgSthv*******Wt fgggtklei
6FAB ysltisnleqediatyfcaaanal)******rtfgggtklei
7FAB atlaitglqaedeadyycasydrsl******rvfgggtkltv
B
H-Chain
1 CDR1 (26-35) CDR2 (50-65) 70
NC6 .8 RvlEgempavica_yLg_WNC6.8RvqlEsgalskpasvQsCkaaytfEywiwvkErpghglewi ei1p**gsgRtnyReKfkakatft
1FDL qvqlkesgpglvapsqslsitctvsgfsltay vnwvrqppgkglewlgsiw***adantdvnsglksrlsis
2F19 qvqlqqsgaelvragssvkmsckasgvtftsvyawvkqrpgqglewicvinp**akaylsynekfkqkttlt
2FBJ evkllesggglvqpggslklscaasgfdfsky,Mwvrqapgkglewigeihp**dsgtinvtpslkdkfiis
2HFL EvqlQQsga'elmkpgasvKisckaSavtfsDvwiwvkQrpghglewigeilp**asaStnvHeRfkgkatft2IG2 evqlvqsgggvvqpgrslrlscsssafifssvamywvrqapgkglewvailw**ddasdahvadsvkurftis
2MCP evklvesggglvqpggslrlscatsaftfsdfymewvrqppgkrlewiaa-srnknkytteysasvkarfivs
3HFM dvqlqesgpslvkpsqtlsltcsvtgdsitsdvwswirkfpgnrleymgyv**yqty sksrisit
4FAB evkldetggglvqpgrpmklscvasgftfs mnwvrqspekglewvaairnkrynvetvvsdsvkgrftis6FAB evqlqqsgvelvragssvkmsckasaptftsnnijwvkqrpgqglewi np**gnayiaynekfkgktt1t
7FAB avqleqsgpglvrpsqtlsltctvsgtsfddyystwvrqppgrglewig wf***vtattlldpslrsrvtm1
71 CDR3 (94-102) 113
NC6.8 adtssNtaymqlSsltsedsAvyycTRaYSS************MdYwgqgtSVtvss
1FDL kdnsksqvflkmnslhtddtaryycarerdyrl***********dywgqgttltvss
2f19 vdrssstaymqlrsltsedaavyfcarsfyaas****dlavyyfdswgqgttltvss
2FBJ rdnaknslylqmskvrsedtalyycarlhyyay**********navwgqgtlvtvsa
2HFL adtssStaymqlNsltsedsGvyycLHaNYD************FdGwgqgtTLtvss
2IG2 rndskntlflqmdslrpedtgvyfcardaahafcssascfgp**dvwgqgtpvtvss
2MCP rdtsqsilylqmnalraedtaiyycarnyvast********wvfdvwgagttvtvss
3HFM rdtsknqyyldlnsvttedtatyycanwda**************dywgqgtlvtvsa
4FAB rddskssvylqmnnlrvedmgiyyctgsyya************mdvwgqgtsvtvss
6FAB vdkssstaymqlrsltsedsavyfcarseyyg"*******vkfdvwgqgttltvss
7FAB vntsknqfslrlssvtaadtavyycarnliagc**********idywgqgslvtvss
FIGURE 2 (A) L-chain V-region sequences of NC6.8 and some of the antibodies that were aligned using the automated antibody structure generation
program, ABGEN. The CDR residues are underlined. The conservative replacements are shown in uppercase, and the nonconservative replacements are
denoted in boldface uppercase for the parent (4FAB) and model sequences alone. Residues are numbered according to Kabat et al. (1991). (B) H-chain
V-region sequences of NC6.8 and some of the antibodies that were aligned using ABGEN. The CDR residues are underlined. The conservative replacements
are shown in uppercase, and the nonconservative replacements are denoted in boldface uppercase for the parent (2HFL) and model sequences alone.
Residues are numbered according to Kabat et al. (1991).
-7.53 x 103 to -7.76 x 103 kcal/mol during 20 ps of the modeled structure with the x-ray (native) were 1.1 and
molecular dynamics. 1.7 A, those between the liganded form and the model were
Examination of the CDRs in the native x-ray structure 1.0 and 1.7 A, respectively. Phi-psi plots of the L- and
showed that some of the canonical features in CDRs Li and H-chain model structures are presented in Fig. 3 A and B; no
Hi were not satisfied (these have been discussed in detail abnormal values were noted.
below) (Chothia and Lesk, 1987). This prompted us to We discuss the comparison of the theoretical model with
examine the x-ray structure of NC6.8 with the ligand bound. the x-ray structures for each of the CDR regions (Tables 2
The rmsd of the main-chain atoms for the L and H chains of and 3).
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FIGURE 3 (A) Phi-psi plot for the NC6.8 model L
chain. (B) Phi-psi plot for the NC6.8 model H chain. B
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LI: The modeled loop and the liganded x-ray structure
are consistent with the canonical structure requirements. H
bonds are formed between the main-chain atoms of L:27b
and L:32 as also L:27d and L:30. L27b, which is a Leucine,
has its side chain pointing into the hydrophobic cavity
between the two ,3 sheets. However, the native x-ray struc-
ture does not satisfy the canonical feature requirement of an
H bond between L:27d and L:30. The backbone rmsd of the
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TABLE 2 rmsd of residues in the L-chain CDRs of the model from the x-ray native and complex structures
L-CDR1 L-CDR2 L-CDR3
rmsd rmsd rmsd rmsd rmsd rmsd
Residue Native Complex Residue Native Complex Residue Native Complex
Ser-26 2.2 1.9 Tyr-49 1.8 2.1 Ser-89 1.1 1.1
Gln-27 1.6 1.4 Arg-50 1.8 2.2 Gln-90 1.6 1.5
Ser-27A 2.5 2.0 Val-51 1.4 1.1 Gly-91 1.8 2.0
Leu-27B 1.3 1.6 Ser-52 1.2 1.0 Thr-92 2.0 1.8
Val-27C 2.2 2.4 Asn-53 1.3 1.5 His-93 1.1 1.4
His-27D 1.3 1.9 Arg-54 2.5 1.8 Val-94 3.6 4.9
Ser-27E 2.5 1.9 Phe-55 1.7 1.6 Pro-95 2.0 2.2
Asn-28 3.6 3.3 Ser-56 1.7 0.9 Tyr-96 2.2 2.3
Gly-29 4.9 4.8 Thr-97 1.6 1.8
Asn-30 4.2 4.1
Thr-31 1.2 1.0
Tyr-32 0.9 1.7
rmsd back 1.8 1.7 rmsd back 0.8 0.6 rmsd back 0.9 0.9
rmsd all 2.1 2.3 rmsd all 1.4 1.4 rmsd all 1.4 1.6
model from the x-ray native and complex structures is 1.6 L3: This nine-residue-long loop maintains all the struc-
and 0.9 A (Fig. 4A and B), and that for all the atoms is 2.1 tural requirements of other canonical U configurations in
and 1.4 A, respectively, and the rmsd between the native the model and the two x-ray structures. L:95 which is a Pro,
and the complex x-ray structures is 0.5 A. is a cis-peptide. Also there is a characteristic H bond be-
L2: The backbone rmsd of the model from the native and tween the main-chain atoms of L:90 and L:97. A side-chain
complex is structures 0.6 and 0.5 A, respectively (Fig. 4 A amide of L:90 forms an H bond with the carbonyls of L:93
and B), and the total rmsd between the model and each of and L:95, and the side-chain oxygen forms an H bond with
the x-ray structures is 1.4 A. The modeled loop satisfies the the amide of L:92. The model structure has a backbone rmsd
conformational requirements of a three-residue turn and of 0.9 A and a total rmsd of 1.4 A (Fig. 4 A and B) and 1.6
packing of the FR against the loop residues. Also, as re- A with the native and complex structures, respectively. The
quired by the canonical configuration, there is an H bond rmsd between the two crystal structures is 0.4 A.
between the main-chain atoms of L:49 and L:53. Both the HI: The backbone rmsd of the modeled structure from
native and the liganded structures satisfy the requirements the native and complex structures is 1.0 and 0.4 A (Fig. 4 C
too, with the rmsd between the native and complex crystal and D). The total rmsd of the model from the native and
structures being 0.4 A. complex x-ray structure is 2.1 and 2.0 A. The Hi loop
TABLE 3 rmsd of residues in the H-chain CDRs of the model from the native and complex structures
H-CDR1 H-CDR2 H-CDR3
rmsd rmsd rmsd rmsd rmsd rmsd
Residue Native Complex Residue Native Complex Residue Native Complex
Gly-26 1.9 1.9 Glu-50 1.4 0.9 Asp-94 2.4 2.1
Tyr-27 3.6 4.1 Ile-51 1.1 0.6 Gly-95 1.8 2.6
Thr-28 2.2 2.7 Leu-52 1.9 1.9 Tyr-96 4.7 4.7
Phe-29 1.1 1.0 Pro-52A 1.9 1.8 Ser-97 6.5 7.4
Ser-30 2.3 1.8 Gly-53 1.6 2.1 Ser-98 8.9 9.1
Glu-31 5.5 5.0 Ser-54 2.3 2.2 Met-100 0.3 10.1
Tyr-32 2.7 2.5 Gly-55 1.8 1.7 Asp-101 2.9 2.9
Trp-33 2.4 1.6 Arg-56 6.6 6.7 Tyr-102 4.2 4.1
Ile-34 1.7 1.4 Thr-57 2.2 2.0
Glu-35 1.6 2.1 Asn-58 1.7 2.0
Tyr-59 1.3 1.6
Arg-60 1.9 1.8
Glu-61 5.1 5.0
Lys-62 2.0 1.3
Phe-63 1.8 1.7
Lys-64 3.4 2.9
Gly-65 1.9 2.0
rmsd back 1.1 0.8 rmsd back 1.2 1.2 rmsd back 2.4 2.7
rmsd all 2.1 2.3 rmsd all 2.4 2.4 rmsd all 3.9 3.9
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FIGURE 4 (A) Stereo drawing of the
main-chain atoms for the NC6.8 native
x-ray structure (dashed lines) and the
NC6.8 model (solid lines) for the L-chain
CDRs. The beginning and ending resi-
dues for each loop are numbered accord-
ing to the system of Kabat et al. (1991).
The rmsd from the x-ray structures and
canonical features of the loops are dis-
cussed in the text and in Table 2. (B)
Stereo drawing of the main-chain atoms
for the NC6.8 with ligand x-ray structure
(dashed lines) and the NC6.8 model (sol-
id lines) for the L-chain CDRs. The be-
ginning and ending residues for each
loop are numbered according to the sys-
tem of Kabat et al. (1991). The rmsd
from the x-ray structures and canonical
features of the loops are discussed in the
text and in Table 2. (C) Stereo drawing of
the main-chain atoms for the NC6.8 na-
tive x-ray structure (dashed lines) and the
NC6.8 model (solid lines) for the
H-chain CDR regions. Beginning and
ending residues for each loop are num-
bered according to the system of Kabat et
al. (1991). The rmsd from the x-ray
structures and canonical features of the
loops are discussed in the text and in
Table 3. (D) Stereo drawing of the main-
chain atoms for the NC6.8 with ligand
x-ray structure (dashed lines) and the
NC6.8 model (solid lines) for the
H-chain CDR regions. Beginning and
ending residues for each loop are num-
bered according to the system of Kabat et
al. (1991). The rmsd from the x-ray
structures and canonical features of the
loops are discussed in the text and in
Table 3.
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maintains all the canonical features, with the side chain of
H:29 buried within the framework and packing against the
side chain of H:34. The Gly at H:26, which is conserved,
introduces the sharp turn that characterizes the first turn in
the Hi loops. In the native structure the distance between
the backbone atoms of H:28 and H:31 is too large to form
an H bond, which is one of the structural requirements of the
canonical feature, whereas the complex x-ray structure sat-
isfies all the canonical requirements. The rmsd between the
native and liganded structures is 0.7 A, with the largest
deviation in Glu H:31. This could explain the large devia-
tion between the native and the model structure.
H2: The H2 loop is 15 residues long and is very similar
to both the x-ray structures, with the backbone rmsd being
0.7 A (native) and 0.9 A (complex) (Fig. 4 C and D) and that
between the two x-ray structures being 0.5 A. The total
rmsd of the model from both the native and complex x-ray
structures is 2.4 A. All the canonical requirements are
satisfied by all three structures, with the H bonds formed
between the main-chain atoms of H:52 and H:56. The loop
region from H:52 to H:56 forms part of the four-residue turn
described by Chothia and co-workers (Chothia et al., 1989)
in which the conformation and position of the four residue
regions are determined by the packing against the VH frame-
work and the identity of the residue at position 71 in
particular. H:71 is an Ala, and this packs against H:52a,
which is a Pro, causing a change in the conformation of the
loop.
H3: The H3 loop involved the maximum replacements
from the parent model. Of the eight residues in the loop only
two were conserved between the two sequences. Also there
are no canonical configurations defined for this loop region
(Chothia and Lesk, 1987). Hence this gave the maximum
deviations from both the native and the complex x-ray
structures, with the backbone rmsd being 2.1 and 2.3 A,
respectively (Fig. 4 C and D) and the rmsd of all the atoms
in the model from both of the crystal structures being 3.9 A.
However, the deviation between the two x-ray structures is
0.8 A.
Competitive ligand binding experiments
The dissociation constant for NC6.8 with the guanidinium
ligand has been determined to be 53 nM (Anchin and
Linthicum, 1993). Ligand binding specificity of NC6.8 was
determined by examination of different analogs with sub-
stitutions at the three major sites (viz., the cyanophenyl
group, the carboxymethyl moiety, and the diphenylmethyl
system). Analogs with substitutions at the cyanophenyl por-
tion, such as chlorophenyl and azidophenyl, exhibited poor
binding (IC50 values in excess of 200 mM). Replacement of
the acetic acid portion of the ligand with a tetrazolylmethyl
significantly reduced binding affinity (IC50 = 32 mM).
Substitutions of groups such as biphenylmethyl, cyclooctyl,
and diethylmethyl for the diphenylmethyl produced only a
slight decrease in ligand binding (IC50 values ranged from
224 to 750 nM), but these observations are not surprising
because the parent ligand was conjugated through the para
position of one of the phenyl rings for preparation of the
immunogen and it is likely that this region of the ligand
would be a minor immunorecognition epitope.
The effects of pH on ligand binding were determined by
changes in the solvent pH of the RIA. The aryl nitrogen
(adjacent to the cyanophenyl ring) has been determined to
have a pKa of 9.3 (M. Sulikowski and D. S. Linthicum,
unpublished observations), and thus at pH 7.0 the aryl
nitrogen and the guanidinium core carries a delocalized
positive charge that may be available for an H bond or a salt
bridge with a corresponding site in the antibody.
Spectroscopic determinations
Absorption and fluorescence spectroscopy were carried out
according to the procedures reported elsewhere (Droupadi
et al., 1993). Quenching of the intrinsic fluorescence of
NC6.8 on addition of increasing quantities of the guani-
dinium ligand was used to measure several aspects of the
molecular complexation. The method of Lehrer (1971) was
used to obtain the maximum fluorescence quenching, by
plotting the flourescence intensities in the absence and
presence of ligand near the saturation point versus the
concentration of the ligand. NC6.8 had a maximum emis-
sion at 332 nm and a monotonic fluorescence quenching
(Qmax = 20%) on addition of the ligand (Table 4). There
was no energy transfer detectable, and the absorption spec-
trum of the ligand did not overlap the emission spectrum of
mAb.
The magnitude of changes in the emission intensity on
association with ligand was related to the concentration of
the ligand. Fig. 5 is a titration curve showing the quenching
of fluorescence intensity on addition of increasing quantities
of the ligand. Maximum changes in relative fluorescence
intensity were observed at ligand concentrations in the
range of 2-30 nM, and saturation was reached near 130 nM.
Equilibrium association constants were evaluated according
to the method of Stinson and Holbrook (1973) in which the
maximum fluorescence quenching is obtained by the double
inverse plot. This value was used to calculate the fractional
TABLE 4 Spectroscopic and thermodynamic parameters for the mAb NC6.8-ligand complex at 250C
Emission Qmax KA DG DH DS
Maximum (nm) (%) (107 L/M) (kcal/mol) (kcallmol) (cal/mol/K)
332 20 1.6 -9.8 -5.5 14.6
Thermodynamic values were derived by van't Hoff analysis (the plot of In KA versus the inverse of absolute of temperature).
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FIGURE 5 Fluorescence emission spectra of the mAb NC6.8 in the
presence of increasing concentrations of the guanidinium ligand, from 0
nM (top curve) to 130 nM (bottom curve), at 25'C in phosphate-buffered
saline (ph 7.4).
occupancy of the binding sites. The intrinsic association
constant determined by fluoresence quenching were ana-
lyzed with the van't Hoff isochore. The slope of the van't
Hoff plot corresponds to the enthalpic change involved in
the binding of mAb to the ligand. NC6.8 MAb had a
0.20
= 0.101
0
515
Wavelength (nm)
positive slope (exothermic); the thermodynamic parameters
calculated for the mAb-ligand complex at 25°C are also
presented in Table 4.
Absorption spectroscopy of the mAb-ligand complex for
NC6.8 and another antisweetener ligand mAb in our collec-
tion, NC10.8, was used to identify the presence, if any, of a
charge-transfer band resulting from the ligand complex-
ation. Although a strong charge-transfer band was observed
for NC10.8, a similar band was not observed for NC6.8
(Fig. 6).
DISCUSSION
Knowledge-based approaches to antibody modeling use
structures from both antigen-bound and antigen-free struc-
tures, and therefore it is not obvious whether the modeled
structure reflects the sweetener-bound or sweetener-free
NC6.8 structure. Inasmuch a high-resolution structures are
available for both the bound and the free states (Guddat et
al., 1994), comparisons of our model are made against both
structures. It should be noted that the above model structure
was used in conjunction with experimental studies to predict
the ligand binding residues before their elucidation by x-ray
crystallography.
c
n1
0
515
Wavelength (nm)
800
FIGURE 6 (A) Absorption spectra of 0.7 mM of mAb NC6.8 in the presence of 0.0, 0.004, 0.012, 0.33, 0.48, 0.90, 1.6, and 2.7 mM of ligand. No
increased absorption is observed in the 300-360-nm range. (B) Absorption spectra of 1.4 mM of a different mAb (clone NC10.8) in the presence of 0.0,
0.002, 0.05, 0.46, 1.24, 1.95, 2.86, 3.98, and 5.38 mM ligand. The observed increase in absorbance near 260 and 280 nm for both mAb is due to the
mAb-ligand complex and free ligand. The increased absorbance in the 300-360-nm range (arrow) is attributed to a charge-transfer complex in NC10.8,
which is not present in NC6.8.
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FIGURE 7 (A) En face stereo rendering of the charges at the van der Waals surface for NC6.8 using the algorithm NCVIEW. The colors are coded
according to the Coulombic charges at the van der Waals surface, with blue representing the positively charged potentials and red representing negatively
charged potentials; other colors (green, cyan, orange, and yellow) render the gradient between these two extremes. Note the "blue" area (which is due to
the side chain of H:56R) at the right of the binding site pocket (arrow) and the "red" areas (which are due to the side chains of H:50E and H:35E) down
in the ligand binding site (center). It is predicted that these three residues interact with the carboxylate and protonated aryl nitrogen of the ligand; the
cyanophenyl portion of the ligand is predicted to project down into the antibody pocket. (B) En face stereo view of the peptide backbone of NC6.8. The
CDR are colored as CDRL1 in blue, CDRL2 in pink, CDRL3 in purple, CDRH1 in red, CDRH2 in green, and CDRH3 in orange.
The competitive analog ligand RIA experiments indi-
cated that the binding pocket is very specific for the cya-
nophenyl moiety of the ligand and cannot accommodate
larger or different (in electronic terms) substituents. Fur-
thermore, the carboxylate portion of the ligand was also
determined to be a very important feature for antibody
recognition. The pH titration experiments suggested that the
protonation of the aryl nitrogen of the ligand was also an
important feature for antibody recognition. As the pH nears
and exceeds the pKa of this nitrogen, the proton is lost,
thereby reducing the capacity of the guanidinium to interact
with the antibody binding site. The overall "zwitterionic"
nature of the ligand has been noted to be an essential
characteristic for its intense sweet taste properties (Muller et
al., 1992). In contrast to that for the charged portions of the
ligand, the nature of the substitutions at the hydrophobic
diphenylmethyl system is not so critical for binding to mAb
NC6.8. We noted that different hydrophobic substitutions at
this site were well tolerated, suggesting that this region of
the ligand interacts with hydrophobic residues in the mAb
or is pointing out from the central mAb binding pocket.
These binding data suggest that the electrostatic nature of
both the ligand and the antibody are important factors in
ligand recognition.
TABLE 5 Comparison of key residues predicted to be in
contact by ligand binding experiments and modeling with
x-ray structure
Predicted Contact
NC174 (Experiments and Model)* X Ray*
Cyanophenyl L:34H (vdW) L:34H (vdW)
L:96Y (vdW) L:96Y (vdW)
H:35E (vdW) H:35E (vdW)
Biphenyl ring L:27DH (vdW) L:27DH (vdW)
L:32Y (vdW) L:32Y (vdW)
H:96Y (vdW) H:96Y (vdW)
Guanidine group H:35E (vdW) H:35E (vdW)
H:50E (vdW) H:50E (hb,vdW)
H:96Y (hb,vdW)
Carboxy H:33W (vdW) H:33W (vdW)
H:56R (hb) H:56R (hb,vdW)
* vdW, van der Waals; hb, hydrogen bonding.
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FIGURE 8 (A) Stereo drawing of the binding site side chains for the nine residues in the model structure predicted to be involved in ligand recognition
with the CDRs (all colored in magenta) compared with their positions in the native x-ray structure (colored in green) NC6.8 Fab. (B) Stereo drawing of
the binding site side chains for the nine residues in the model structure predicted to be involved in ligand recognition with the CDR regions (all colored
in magenta) compared with their positions in the x-ray structure (colored in cyan) of the liganded NC6.8 Fab.
Inspection of the NC6.8 Fv model reveals two acidic
residues, H:35E and H:50E, deep in the putative ligand
binding pocket. These are predicted to provide a negative
electrostatic potential for complementary charge interac-
tions with the positive guanidinium group of the ligand. Fig.
7 A shows the stereo en face graphical rendering of the
electrostatic surface of the NC6.8 Fv model obtained with
the NCVIEW algorithm (Purvis and Culberson, 1986). The
negatively charged contours (colored in red in the center
pocket) highlight the predicted H:50E and H:35E charge
interaction sites. Another predicted site for ligand recogni-
tion is the basic residue H:56R (CDR2 of the H chain, seen
in Fig. 7 A in blue), which interacts with the carboxylate
moeity of the ligand through the formation of a salt bridge.
Based on this Fv model and ligand binding data, the
cyanophenyl portion of the ligand is predicted to point down
into the pocket (Fig. 7 B). To determine whether Trp resi-
dues participate in the ligand recognition we examined the
mAb-ligand complex for steady-state quenching of intrinsic
Trp fluorescence. We observed an isotonic quenching (i.e.,
no hypsochromic shift), suggesting the participation of a
Trp that is not highly exposed to solvent. NC6.8 has five
V-region Trp residues. Four of these, H:36W, H:47W,
H:103W, and L:35W, appear in 92-99% of all known
murine V-region antibody sequences. The high degree of
conservation of these residues suggests a structural role for
them. It is unlikely that these are involved in the quenching
reaction because of their packing interactions and deep
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buried positions relative to the binding pocket. In sharp
contrast, the Trp located at H:33 is found in only 3% of
known antibody sequences. This Trp is in the combining
site as observed in other emperically solved Fab structures
(Herron et al., 1989; Sheriff et al., 1987). Based on these
observations, we predict that H:33W in mAb NC6.8 is
involved in the complexation with the ligand and responsi-
ble for the observed ligand-induced fluorescence quench-
ing. The absence of a blue shift in the fluorescence quench-
ing supports the deep-pocket location of this residue in the
model.
We used data from absorption spectroscopy to determine
whether a charge transfer band could be observed in the
mAb-ligand complex. We have observed this type of spec-
tral feature in other NC mAb-ligand complexes (e.g.,
NC10.8) and have attributed the observed charge-transfer
band to the formation of a f-wr interaction between an
electron-rich donor Trp in the mAb and the electron-poor
cyanophenyl ring of the ligand (Anchin and Linthicum,
1993). In the case of NC6.8 we predict that the cyanophenyl
ring ligand does not undergo a u--7r stacking arrangement
with H:33W, because of the absence of any observable
charge-transfer band.
The model structure suggests the role of several polar
interactions in ligand binding. This in turn would lead to
large enthalpic contributions to thermodynamics of binding
of the ligand to the antibody. We examined the NC6.8-
ligand complexation at different temperatures to evaluate
the thermodynamic parameters that govern the association
process. The intrinsic association constant corresponds to
the free energy changes as calculated by the van't Hoff
analysis. This analysis shows that the interaction for this
mAb is enthalpically driven (P. R. Droupadi and D. S.
Linthicum, unpublished results).
Based on the modeled Fv fragment and experimental
studies of ligand binding, we have predicted the identity and
position of several key residues responsible for ligand rec-
ognition and binding (Table 5). Fig. 8 A shows a stereo
drawing of the nine residues predicted by the modeling,
compared with their positions in the native Fab x-ray struc-
tures. Fig. 8 B shows the nine residues predicted compared
with the ligand-complex mAb. As is apparent from Fig. 8 A
and B, H:33W (observed in ligand-induced fluorescence
quenching), the negatively charged residues H:35E and
H:SOE (which provide the negatively charged environment
for the guanidinium moeity in the ligand), H:56R (which
provides the counterion for the acetic acid moeity), and
L:34H deep in the binding pocket (which is in contact with
the cyanophenyl group of the ligand) are identified as key
residues involved in antigen binding.
In summary, the combination of computer-aided molec-
ular modeling, competitive analog ligand binding, and flu-
orescence spectroscopy can facilitate the prediction of the
antigen combining sites on an antibody, as demonstrated in
this study. Additional experimental and theoretical studies
involving this and other high-affinity mAb with the super-
potent guanidinium sweeteners are currently under way.
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